Journal: Scientific Reports

Article Title: Exposure to mycotoxins from the consumption of corn-based breakfast cereals in the United Arab Emirates

doi: 10.1038/s41598-024-74529-8

Figure Lengend Snippet: Major mycotoxins, their characteristics and limits (Yu & Pedroso, 2023).

Article Snippet: Specifically, the RIDASCREEN AFB1 30/15 (R1211), OTA 30/15 (R1312), ZEA (R1401), FUM (R3401), and DON (R5906) test kits from R-biopharm, Germany, were utilized.

Techniques:

Journal: Scientific Reports

Article Title: Exposure to mycotoxins from the consumption of corn-based breakfast cereals in the United Arab Emirates

doi: 10.1038/s41598-024-74529-8

Figure Lengend Snippet: Tolerable daily intake of mycotoxins.

Article Snippet: Specifically, the RIDASCREEN AFB1 30/15 (R1211), OTA 30/15 (R1312), ZEA (R1401), FUM (R3401), and DON (R5906) test kits from R-biopharm, Germany, were utilized.

Techniques:

Journal: Scientific Reports

Article Title: Exposure to mycotoxins from the consumption of corn-based breakfast cereals in the United Arab Emirates

doi: 10.1038/s41598-024-74529-8

Figure Lengend Snippet: BMDL10 of mycotoxins.

Article Snippet: Specifically, the RIDASCREEN AFB1 30/15 (R1211), OTA 30/15 (R1312), ZEA (R1401), FUM (R3401), and DON (R5906) test kits from R-biopharm, Germany, were utilized.

Techniques:

Journal: Scientific Reports

Article Title: Exposure to mycotoxins from the consumption of corn-based breakfast cereals in the United Arab Emirates

doi: 10.1038/s41598-024-74529-8

Figure Lengend Snippet: Mean, range and limits for different mycotoxins.

Article Snippet: Specifically, the RIDASCREEN AFB1 30/15 (R1211), OTA 30/15 (R1312), ZEA (R1401), FUM (R3401), and DON (R5906) test kits from R-biopharm, Germany, were utilized.

Techniques:

Journal: Scientific Reports

Article Title: Exposure to mycotoxins from the consumption of corn-based breakfast cereals in the United Arab Emirates

doi: 10.1038/s41598-024-74529-8

Figure Lengend Snippet: Percentage distribution of mycotoxin occurrence according to various variables.

Article Snippet: Specifically, the RIDASCREEN AFB1 30/15 (R1211), OTA 30/15 (R1312), ZEA (R1401), FUM (R3401), and DON (R5906) test kits from R-biopharm, Germany, were utilized.

Techniques: Significance Assay, Chocolate

Journal: Scientific Reports

Article Title: Exposure to mycotoxins from the consumption of corn-based breakfast cereals in the United Arab Emirates

doi: 10.1038/s41598-024-74529-8

Figure Lengend Snippet: EDI, HQ and MoE for different mycotoxins.

Article Snippet: Specifically, the RIDASCREEN AFB1 30/15 (R1211), OTA 30/15 (R1312), ZEA (R1401), FUM (R3401), and DON (R5906) test kits from R-biopharm, Germany, were utilized.

Techniques:

Journal: Therapeutic Drug Monitoring

Article Title: Fluorescence-Based Lateral Flow Immunoassay for Quantification of Infliximab: Analytical and Clinical Performance Evaluation

doi: 10.1097/FTD.0000000000001176

Figure Lengend Snippet: Demographic Characteristics of Patients

Article Snippet: In this study, the analytical and clinical performance of AFIAS IFX was compared with that of 3 commercially available ELISA kits, LISA TRACKER (Theradiag, France), RIDASCREEN IFX monitoring (R-Biopharm, UK), and ImmunoGuide (AybayTech Biotechnology, Turkey), hereafter referred to as LISA, RIDA, and ImmunoGuide, using clinical samples.

Techniques:

Journal: Therapeutic Drug Monitoring

Article Title: Fluorescence-Based Lateral Flow Immunoassay for Quantification of Infliximab: Analytical and Clinical Performance Evaluation

doi: 10.1097/FTD.0000000000001176

Figure Lengend Snippet: Passing–Bablok regression analysis of quantifiable (n = 50) IFX drug levels analyzed using 3 different ELISA kits, (A) LISATracker, (B) RIDAScreen, and (C) ImmunoGuide, compared with AFIAS IFX. The data show the results of samples (n = 50) from treated patients treated with Remicade. The regression equation (blue solid line) reveals a constant difference (the regression line intercept and slope). The red dotted lines indicate the 95% CI. The green dotted line is the identity line.

Article Snippet: In this study, the analytical and clinical performance of AFIAS IFX was compared with that of 3 commercially available ELISA kits, LISA TRACKER (Theradiag, France), RIDASCREEN IFX monitoring (R-Biopharm, UK), and ImmunoGuide (AybayTech Biotechnology, Turkey), hereafter referred to as LISA, RIDA, and ImmunoGuide, using clinical samples.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Therapeutic Drug Monitoring

Article Title: Fluorescence-Based Lateral Flow Immunoassay for Quantification of Infliximab: Analytical and Clinical Performance Evaluation

doi: 10.1097/FTD.0000000000001176

Figure Lengend Snippet: Passing–Bablok regression analysis of quantifiable (n = 50) IFX drug levels analyzed using 3 different ELISA kits, (A) LISATracker, (B) RIDAScreen, and (C) ImmunoGuide, compared with AFIAS IFX. The data show the results of samples (n = 50) from patients treated with CT-P13. The regression equation (blue solid line) reveals a constant difference (the regression intercept and slope). The red dotted lines indicate the 95% CI. The green dotted line is the identity line.

Article Snippet: In this study, the analytical and clinical performance of AFIAS IFX was compared with that of 3 commercially available ELISA kits, LISA TRACKER (Theradiag, France), RIDASCREEN IFX monitoring (R-Biopharm, UK), and ImmunoGuide (AybayTech Biotechnology, Turkey), hereafter referred to as LISA, RIDA, and ImmunoGuide, using clinical samples.

Techniques: Enzyme-linked Immunosorbent Assay